Featured Opinions
Helping Patients Learn Healthy Habits
Building for lasting behavior change with a patient-centric, research-driven approach to health innovation
Drug repurposing could help drive orphan drug access if pharma can accept the risks
Why Pharma Needs to Understand Population Health
by Rita Numerof
In the new health ecosystem, pharma needs to know a lot more about population health
Out of the Shadows: Mental Health in Asia Pacific
by Marc Yates
Asia Pacific is the third largest market for mental health medicines but there are substantial obstacles to overcome before pharma – and patients – can reap the benefits
PSPs: Avoiding the Pitfalls, Part 2
Patient support programs are fast becoming ‘cost of entry’ for new drugs and the pressure to deliver differentiated services with measurable results is building across the industry
Innovation, Sustainability, Prosperity: Japan’s Healthcare Vision
by Marc Yates
Japan is looking to its young people to find solutions to its healthcare challenges
The Pharma Business Model: How to Avoid the Innovator's Dilemma
Pharma needs to adopt the business models of tech companies if it is to flourish
ePROs: Why We Should Be Mobile-First
Capturing electronic patient-reported outcomes via a mobile device is a growing trend but you need to think mobile-first
Delivering effective patient support programs (PSPs) is rapidly becoming an essential component of patient access but there are many pitfalls to avoid
Living with NASH: An Unexpected Diagnosis
With no current licensed treatments, the liver disease NASH represents a huge opportunity for pharma – if it understands patient needs
Don’t Just Digitize. Embrace Digitalization
Digitizing an analogue process may deliver benefits but only a radical rethink will bring true success
6 Strategies for a Value-Based World
by Mark Feeney
The shift from volume to value is forcing a rethink of pharma fundamentals. Here are six areas to focus on
Ageing Asia: What Does the Future Hold?
by Marc Yates
Growing elderly populations across Asia are putting strain on healthcare systems and budgets but opportunities abound for innovative pharma companies
The Patient Journey: A Tool for Market Access?
A greater understanding of the patient journey is rapidly becoming an essential tool for market access
Navigating South Korea’s Healthcare Paradox
by Marc Yates
South Korea is a land of extremes and contradictions, yet there are many opportunities for pharma
How industry is coming together to speed up clinical trials
The Role of Post-Market Studies in Market Access
by Rita Numerof
Post-market studies are critical in responding to the increasing demand for data on economic and clinical value
Living with Lupus: Breaking the Silence
Lupus is an almost invisible disease, yet can have considerable impact on patients' quality of life, but there is much that pharma can do to help
by James Wright
Many companies are actively working on the development of 'biobetters' - improved versions of originator biological drugs - but are these drugs worth the investment?
Seeing the Larger Picture on Patient Risk
In the era of value-based care, life science companies will be called upon to take on more risk for patient care – but how much risk are they willing to accept?
Thinking Machines: From Magic to Normal
With big data come big challenges - AI and big data have the potential to transform medicine but only if we keep an open dialogue about associated issues and challenges
Nutrition Market in Brazil: Growth Against the Odds
by Marc Yates
Economic change and rising health consciousness have lit a fuse under the Brazilian nutrition market
5 keys to Unlock Digital Transformation Success
by Will Reece
Digital transformation inside out and upside down
New Ways to Pay for Low-Priority Drug Trials
Companies cannot afford to conduct trials for every asset in their early-stage pipelines - unless they team up with new investors
by Jeff Elton
AI, machine learning and cognitive computing may be changing healthcare, but it's not all plain sailing.